The MET exon 14 skipping mutation is found in approximately 3% of lung 
adenocarcinomas and slightly more than 2% of lung squamous cell carcinomas. In 
recent years, more and more evidence has shown that MET inhibitors have achieved 
good anti-tumor effect in patients with MET exon 14 skipping mutation, 
suggesting that MET exon 14 skipping mutation may be a new target for NSCLC 
patients. Patients with positive MET exon 14 skipping mutation are recommended 
to be administered MET inhibitors, and crizotinib is recommended by the NCCN 
guideline. Due to the presence of gene amplification, second site mutation, 
bypass activation, and pathological type transformation, one of the inevitable 
problems of targeted therapy is drug resistance. If type I MET inhibitors 
(crizotinib, capmatinib, tepotinib, savolitinib) drug resistance is developed, 
type II MET inhibitors (cabozantinib, glesatinib, merestinib) can be considered.